Inaugural DNDi training for health & science journalists in Kampala

In early October, 18 journalists from 11 African countries converged in Kampala, Uganda for DNDi’s first-ever training on health and science journalism. The three-day training was conducted during a week of workshops and meetings related to the work of DNDi and its many partners, culminating in the 11th DNDi Partners’ Meeting on 4 October 2018.

Malaysia takes the lead on a public health approach to hepatitis C with new initiative to enhance diagnosis & treatment

Doctor in a hospital in Malaysia

New agreement between Clinical Research Malaysia & FIND on R&D for hepatitis C diagnostic tests continues an existing Malaysian partnership with DNDi for hepatitis C treatment

The Foundation for Innovative New Diagnostics (FIND) and Clinical Research Malaysia (CRM), both DNDi partners, recently signed a memorandum of understanding (MoU) to collaborate in the research and development of an innovative hepatitis C diagnostic testing strategy.

DNDi announces new Director of Neglected Tropical Diseases

Dr Nathalie Strub-Wourgaft examines patient in Sudan.

Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme

DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.

DNDi welcomes Astellas to the NTD Drug Discovery Booster

Scientist holding a test tube

The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.

R&D Portfolio Update March 2018: DNDi Sleeping sickness programme

Medical staff looking into a microscope while screening patients in DRC

Phase II/III study results confirmed that fexinidazole, DNDi’s first new chemical entity is safe and effective, and presents significant advantages over current treatment as it removes the need for lumbar puncture and systematic patient hospitalization. A regulatory dossier has been submitted to the European Medicines Agency for fexinidazole as the first all-oral treatment for sleeping sickness.

R&D Portfolio Update March 2018: DNDi Leishmaniasis programme

VL patient under treatment in Sadar Hospital Chapra

Three new chemical entities entered the pre-clinical pipeline, bringing to six the number of new compounds progressing in the leishmaniasis portfolio, with two already nominated as clinical candidates to progress to Phase I. The first patient was recruited in India in Phase II studies to test new treatments for PKDL, while clinical sites were being prepared in Bangladesh and Sudan. A site was initiated in Sudan for a Phase III study to test a new combination treatment for leishmaniasis in the African region. In Latin America, a Phase II study on new combination treatments for cutaneous leishmaniasis progressed well.

R&D Portfolio Update March 2018: DNDi Chagas disease programme

Young girl holding a flyer on Chagas disease

Two Phase II trials are ongoing, with the study in Bolivia on benznidazole for improved treatment of chronic indeterminate Chagas disease having completed recruitment at the end of 2017, and a study in Spain in the early stages of patient recruitment to evaluate fexinidazole as Chagas treatment. A pilot project to increase access to diagnosis and treatment in five endemic communities in Colombia showed excellent interim results and will report one-year results in mid-2018. In 2018, DNDi and Fundación Mundo Sano will launch a new Chagas Disease Regional Access Framework.

R&D Portfolio Update March 2018: DNDi Mycetoma programme

Women from the research staff testing drugs

The first-ever double-blind, randomized clinical trial for eumycetoma (fungal mycetoma), being conducted in Sudan, had enrolled 20 patients by the end of 2017. The primary objective of the study is to demonstrate the superiority of fosravuconazole over the current treatment, itraconazole.

R&D Portfolio Update March 2018: DNDi Paediatric HIV programme

Mother sat on the bed with her son and his medication to treat HIV

A first-line “4-in-1” fixed-dose combination (abacavir/lamivudine/lopinavir/ritonavir) is on track to be submitted for registration in late 2018. Preliminary results from the LIVING study for an interim optimized paediatric formulation were presented at the end of 2017, showing that these “oral pellets” are effective, well tolerated and well accepted by caregivers and children.

DNDi reçoit le Prix 2017 de l’Innovation à Genève pour récompenser son action en faveur des populations les plus négligées

A l’occasion de l’Evénement économique 2017 du 9 novembre dernier, la Chambre de commerce, d’industrie et des services de Genève (CCIG), le Département de la sécurité et de l’économie (DSE) et l’Office de Promotion des Industries et des Technologies (OPI) ont décerné le Prix 2017 de l’innovation à l’initiative Médicaments contre les Maladies Négligées (DNDi).

GARDP at one: R&D programmes getting underway

GARDP at one year old

GARDP has set up its team, scientific advisory committee, and R&D strategy. Three programmes are underway: neonatal sepsis, gonorrhoea, and an initiative to recover and connect the vital knowledge of scientists in antibiotic drug development. In recent weeks, both the G20 Health Ministers and outgoing WHO Director-General Margaret Chan have expressed support for GARDP and called for more R&D into drug-resistant infections.